Report cover image

Alzheimer's Disease Diagnostics and Therapeutics Market Size, Share, and Outlook, H2-2025 Report- By Therapeutics (Marketed Drugs, Pipeline Drugs), By Diagnostics (Lumbar Puncture Test, Computed Tomography Scan, Magnetic Resonance Imaging, Electroencephal

Publisher VPA Research
Published Sep 01, 2025
Length 192 Pages
SKU # VPA20331504

Description

Alzheimer's Disease Diagnostics and Therapeutics Market Outlook
The global Alzheimer's Disease Diagnostics and Therapeutics Market Size is valued at $15.2 Billion in 2025 and is forecast to reach $37.3 Billion in 2032 at a CAGR of 13.7%.
The Alzheimer's Disease Diagnostics and Therapeutics Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Alzheimer's Disease Diagnostics and Therapeutics Market segments across 22 countries from 2021 to 2032. Key segments covered include By Therapeutics (Marketed Drugs, Pipeline Drugs), By Diagnostics (Lumbar Puncture Test, Computed Tomography Scan, Magnetic Resonance Imaging, Electroencephalography, Positron Emission Tomography Scan, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.

Alzheimer's Disease Diagnostics and Therapeutics Market Insights, 2025
The Alzheimer's disease market in 2025 is advancing with new diagnostic imaging agents, biomarker assays, and disease-modifying therapies. Recent developments include tau and amyloid PET tracers for early detection and monoclonal antibodies targeting amyloid-beta accumulation. Companies are also introducing precision medicine approaches that leverage genetic profiling and fluid biomarkers. Research focuses on combination regimens addressing both symptomatic relief and neurodegeneration slowing. Hospitals and memory clinics are integrating AI-assisted cognitive assessment tools to improve diagnostic accuracy. Regulatory approvals for novel biologics and therapeutic interventions are enabling faster patient access. Overall, the market reflects a trend toward early detection, personalized therapy, and holistic management strategies in Alzheimer's care.

Five Trends Shaping the Global Alzheimer's Disease Diagnostics and Therapeutics Market in 2025 and Beyond
The global Alzheimer's Disease Diagnostics and Therapeutics Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.

What are the Biggest Opportunities for Growth in the Alzheimer's Disease Diagnostics and Therapeutics Industry?
The Alzheimer's Disease Diagnostics and Therapeutics Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Alzheimer's Disease Diagnostics and Therapeutics Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.

Alzheimer's Disease Diagnostics and Therapeutics Market Segment Insights
The Alzheimer's Disease Diagnostics and Therapeutics Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Therapeutics (Marketed Drugs, Pipeline Drugs), By Diagnostics (Lumbar Puncture Test, Computed Tomography Scan, Magnetic Resonance Imaging, Electroencephalography, Positron Emission Tomography Scan, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.

Alzheimer's Disease Diagnostics and Therapeutics Industry Value Chain
The chapter identifies potential companies and their operations across the global Alzheimer's Disease Diagnostics and Therapeutics Industry ecosystem. It assists decision-makers in evaluating global Alzheimer's Disease Diagnostics and Therapeutics Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.

Scenario Analysis and Forecasts
Strategic planning in the Alzheimer's Disease Diagnostics and Therapeutics Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.

Asia Pacific Alzheimer's Disease Diagnostics and Therapeutics Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Alzheimer's Disease Diagnostics and Therapeutics Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.

United States Alzheimer's Disease Diagnostics and Therapeutics Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Alzheimer's Disease Diagnostics and Therapeutics Market.

Europe Alzheimer's Disease Diagnostics and Therapeutics Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Alzheimer's Disease Diagnostics and Therapeutics Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Alzheimer's Disease Diagnostics and Therapeutics Industry competitiveness. The report analyses the key Alzheimer's Disease Diagnostics and Therapeutics Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.

Latin American Alzheimer's Disease Diagnostics and Therapeutics Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Alzheimer's Disease Diagnostics and Therapeutics Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.

Middle East and Africa Alzheimer's Disease Diagnostics and Therapeutics Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Alzheimer's Disease Diagnostics and Therapeutics Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.

Competitive Landscape – How Alzheimer's Disease Diagnostics and Therapeutics Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Alzheimer's Disease Diagnostics and Therapeutics Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes AbbVie Inc, Adamas Pharmaceuticals Inc, AstraZeneca PLC, Biogen Inc, Bristol-Myers Squibb Company, Corium Inc, Eisai Co. Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Lupin Ltd, Merz Pharma GmbH & Co. KGaA, Siemens Healthineers AG, Teva Pharmaceutical Industries Ltd, Zydus Cadila. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.

Alzheimer's Disease Diagnostics and Therapeutics Market Scope
Leading Segments
By Therapeutics
Marketed Drugs
  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonist

  • Pipeline Drugs
    By Diagnostics
    Lumbar Puncture Test
    Computed Tomography Scan
    Magnetic Resonance Imaging
    Electroencephalography
    Positron Emission Tomography Scan
    Others

    Leading Companies
    AbbVie Inc
    Adamas Pharmaceuticals Inc
    AstraZeneca PLC
    Biogen Inc
    Bristol-Myers Squibb Company
    Corium Inc
    Eisai Co. Ltd
    Eli Lilly and Company
    F. Hoffmann-La Roche AG
    Johnson & Johnson
    Lupin Ltd
    Merz Pharma GmbH & Co. KGaA
    Siemens Healthineers AG
    Teva Pharmaceutical Industries Ltd
    Zydus Cadila

    Geographies
    North America- US, Canada, Mexico
    Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
    Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
    Latin America- Brazil, Argentina, Others
    Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

    Reasons to Buy the Report
  • Make informed decisions with 12-year forecasts across 22 countries and multiple market segments.
  • Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry.
  • Gain insights into the competitive landscape, including company profiles, financials, and strategic moves.
  • Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations.
  • Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade.
  • Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions.
  • Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
  • Table of Contents

    192 Pages
    1. Table of Contents
    List of Figures and Tables
    2. Executive Summary
    2.1 Key Highlights
    2.1.1 Alzheimer's Disease Diagnostics and Therapeutics Market Size Outlook, 2018-2024 and 2025-2032
    2.1.2 Largest Alzheimer's Disease Diagnostics and Therapeutics Market Types and Applications
    2.1.3 Fastest Growing Segments
    2.1.4 Potential Markets
    2.1.5 Market Concentration
    2.2 Market Scope and Segmentation
    2.2.1 Market Scope- Segments
    2.2.2 Market Scope- Countries
    2.2.3 Macroeconomic and Demographic Outlook
    2.2.4 Abbreviations
    2.2.5 Units and Currency Conversions
    3. Research Methodology
    3.1 Primary Research Surveys
    3.2 Secondary Data Sources
    3.3 Data Triangulation
    3.4 Forecast Methodology
    3.5 Assumptions and Limitations
    4. Introduction to Global Alzheimer's Disease Diagnostics and Therapeutics Market in 2025
    4.1 Industry Panorama
    4.2 Leading Companies Profiled in the Study
    4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
    4.4 Market Dynamics
    4.4.1 Market Dynamics- Trends and Drivers
    4.4.2 Market Dynamics- Opportunities and Challenges
    4.5 Regional Analysis
    4.6 Porter’s Five Force Analysis
    4.6.1 Intensity of Competitive Rivalry
    4.6.2 Threat of New Entrants
    4.6.3 Threat of Substitutes
    4.6.4 Bargaining Power of Buyers
    4.6.5 Bargaining Power of Suppliers
    4.7 Alzheimer's Disease Diagnostics and Therapeutics Market Industry Value Chain Analysis
    4.7.1 Stage of Value Chain
    4.7.2 Key Activities of Companies
    4.7.3 Companies Included in Each Stage
    4.7.4 Key Insights
    5. Alzheimer's Disease Diagnostics and Therapeutics Market Outlook to 2032
    5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
    5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
    5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
    By Therapeutics
    Marketed Drugs
    -Cholinesterase Inhibitors
    -NMDA Receptor Antagonist
    Pipeline Drugs
    By Diagnostics
    Lumbar Puncture Test
    Computed Tomography Scan
    Magnetic Resonance Imaging
    Electroencephalography
    Positron Emission Tomography Scan
    Others
    6. Global Alzheimer's Disease Diagnostics and Therapeutics Market Outlook across Growth Scenarios
    6.1 Low Growth Scenario
    6.2 Base/Reference Case
    6.3 High Growth Scenario
    6. North America Alzheimer's Disease Diagnostics and Therapeutics Market Size Outlook
    6.1 Key Market Statistics, 2024
    6.2 North America Alzheimer's Disease Diagnostics and Therapeutics Market Trends and Growth Opportunities
    6.2.1 North America Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Type
    6.2.2 North America Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Application
    6.3 North America Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Country
    6.3.1 The US Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    6.3.2 Canada Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    6.3.3 Mexico Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    7. Europe Alzheimer's Disease Diagnostics and Therapeutics Market Size Outlook
    7.1 Key Market Statistics, 2024
    7.2 Europe Alzheimer's Disease Diagnostics and Therapeutics Market Trends and Growth Opportunities
    7.2.1 Europe Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Type
    7.2.2 Europe Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Application
    7.3 Europe Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Country
    7.3.2 Germany Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    7.3.3 France Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    7.3.4 The UK Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    7.3.5 Spain Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    7.3.6 Italy Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    7.3.7 Russia Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    7.3.8 Rest of Europe Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    8. Asia Pacific Alzheimer's Disease Diagnostics and Therapeutics Market Size Outlook
    8.1 Key Market Statistics, 2024
    8.2 Asia Pacific Alzheimer's Disease Diagnostics and Therapeutics Market Trends and Growth Opportunities
    8.2.1 Asia Pacific Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Type
    8.2.2 Asia Pacific Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Application
    8.3 Asia Pacific Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Country
    8.3.1 China Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    8.3.2 India Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    8.3.3 Japan Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    8.3.4 South Korea Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    8.3.5 Australia Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    8.3.6 South East Asia Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    8.3.7 Rest of Asia Pacific Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    9. South America Alzheimer's Disease Diagnostics and Therapeutics Market Size Outlook
    9.1 Key Market Statistics, 2024
    9.2 South America Alzheimer's Disease Diagnostics and Therapeutics Market Trends and Growth Opportunities
    9.2.1 South America Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Type
    9.2.2 South America Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Application
    9.3 South America Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Country
    9.3.1 Brazil Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    9.3.2 Argentina Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    9.3.3 Rest of South and Central America Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    10. Middle East and Africa Alzheimer's Disease Diagnostics and Therapeutics Market Size Outlook
    10.1 Key Market Statistics, 2024
    10.2 Middle East and Africa Alzheimer's Disease Diagnostics and Therapeutics Market Trends and Growth Opportunities
    10.2.1 Middle East and Africa Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Type
    10.2.2 Middle East and Africa Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Application
    10.3 Middle East and Africa Alzheimer's Disease Diagnostics and Therapeutics Market Outlook by Country
    10.3.1 Saudi Arabia Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    10.3.2 The UAE Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    10.3.3 Rest of Middle East Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    10.3.4 South Africa Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    10.3.5 Egypt Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    10.3.6 Rest of Africa Alzheimer's Disease Diagnostics and Therapeutics Market Outlook, 2021- 2032
    11. Company Profiles
    11.1 Leading 10 Companies
    AbbVie Inc
    Adamas Pharmaceuticals Inc
    AstraZeneca PLC
    Biogen Inc
    Bristol-Myers Squibb Company
    Corium Inc
    Eisai Co. Ltd
    Eli Lilly and Company
    F. Hoffmann-La Roche AG
    Johnson & Johnson
    Lupin Ltd
    Merz Pharma GmbH & Co. KGaA
    Siemens Healthineers AG
    Teva Pharmaceutical Industries Ltd
    Zydus Cadila
    11.2 Overview
    11.3 Products and Services
    11.4 SWOT Profile
    12. Appendix
    12.1 Subscription Options
    12.2 Customization Options
    12.3 Publisher Details
    How Do Licenses Work?
    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.